PROGNOSTIC FACTORS IN PATIENTS WITH INTERMEDIATE AND HIGH RISK STAGE TA T1 PAPILLARY CARCINOMA OF THE BLADDER TREATED WITH MAINTENANCE EPIRUBICIN OR MAINTENANCE BACILLUS CALMETTE-GUERIN. RESULTS OF EORTC GU GROUP STUDY 30911

PROGNOSTIC FACTORS IN PATIENTS WITH INTERMEDIATE AND HIGH RISK STAGE Ta T1 PAPILLARY CARCINOMA OF THE BLADDER TREATED WITH MAINTENANCE EPIRUBICIN OR MAINTENANCE BACILLUS CALMETTE-GUERIN. RESULTS OF EORTC GU GROUP STUDY 30911

10.1016/s0022-5347(08)61718-8 ◽

2008 ◽

Vol 179 (4S) ◽

pp. 586-586

Author(s):

Richard Sylvester ◽

Willem Oosterlinck ◽

Maurizio Brausi ◽

Wim J Kirkels ◽

Fernando Calais Da Silva ◽

...

Keyword(s):

Prognostic Factors ◽

High Risk ◽

Papillary Carcinoma ◽

Re: Side Effects of bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-Risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-Third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG

10.1016/j.juro.2014.09.034 ◽

2014 ◽

Vol 192 (6) ◽

pp. 1641-1641

Author(s):

David P. Wood

Keyword(s):

Side Effects ◽

High Risk ◽

Papillary Carcinoma ◽

Phase 3 ◽

Full Dose ◽

INTRAVESICAL INSTILLATION OF EPIRUBICIN, BACILLUS CALMETTE-GUERIN AND BACILLUS CALMETTE-GUERIN PLUS ISONIAZID FOR INTERMEDIATE AND HIGH RISK TA, T1 PAPILLARY CARCINOMA OF THE BLADDER: A EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER GENITO-URINARY GROUP RANDOMIZED PHASE III TRIAL

10.1016/s0022-5347(05)65966-6 ◽

2001 ◽

Vol 166 (2) ◽

pp. 476-481 ◽

Cited By ~ 93

Author(s):

ADRIAN P.M. VAN DER MEIJDEN ◽

MAURIZIO BRAUSI ◽

VICTOR ZAMBON ◽

WIM KIRKELS ◽

CHRISTINE DE BALINCOURT ◽

...

Keyword(s):

High Risk ◽

Papillary Carcinoma ◽

Intravesical Instillation ◽

Phase Iii ◽

European Organization ◽

Phase Iii Trial ◽

Side Effects of Bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG

European Urology ◽

10.1016/j.eururo.2013.07.021 ◽

2014 ◽

Vol 65 (1) ◽

pp. 69-76 ◽

Cited By ~ 122

Author(s):

Maurizio Brausi ◽

Jorg Oddens ◽

Richard Sylvester ◽

Aldo Bono ◽

Cees van de Beek ◽

...

Keyword(s):

Side Effects ◽

High Risk ◽

Papillary Carcinoma ◽

Phase 3 ◽

Full Dose ◽

INTRAVESICAL INSTILLATION OF EPIRUBICIN, BACILLUS CALMETTE-GUERIN AND BACILLUS CALMETTE-GUERIN PLUS ISONIAZID FOR INTERMEDIATE AND HIGH RISK TA, T1 PAPILLARY CARCINOMA OF THE BLADDER

10.1097/00005392-200108000-00016 ◽

2001 ◽

pp. 476-481 ◽

Cited By ~ 7

Author(s):

ADRIAN P. M. VAN DER MEIJDEN ◽

MAURIZIO BRAUSI ◽

VICTOR ZAMBON ◽

WIM KIRKELS ◽

CHRISTINE DE BALINCOURT ◽

...

Keyword(s):

High Risk ◽

Papillary Carcinoma ◽

Intravesical Instillation ◽

Re: Richard J. Sylvester, Maurizio A. Brausi, Wim J. Kirkels, et al. Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder. Eur Urol 2010;57:766–73

European Urology ◽

10.1016/j.eururo.2010.02.037 ◽

2010 ◽

Vol 57 (6) ◽

pp. e57

Author(s):

Tommaso Cai ◽

Lorenzo Giuseppe Luciani ◽

Gianni Malossini

Keyword(s):

High Risk ◽

Urothelial Carcinoma ◽

Phase 3 ◽

Term Efficacy ◽

Carcinoma Of The Bladder ◽

Intravesical Instillations

Faculty Opinions recommendation of Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717964808.793498086 ◽

2014 ◽

Author(s):

Alexander Bachmann ◽

Jan Ebbing

Keyword(s):

High Risk ◽

Urinary Bladder ◽

Papillary Carcinoma ◽

Randomized Study ◽

Full Dose

Faculty Opinions recommendation of Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717964808.793466279 ◽

2012 ◽

Author(s):

Mark Gonzalgo

Keyword(s):

High Risk ◽

Urinary Bladder ◽

Papillary Carcinoma ◽

Randomized Study ◽

Full Dose

Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder

European Urology ◽

10.1016/j.eururo.2009.12.024 ◽

2010 ◽

Vol 57 (5) ◽

pp. 766-773 ◽

Cited By ~ 225

Author(s):

Richard J. Sylvester ◽

Maurizio A. Brausi ◽

Wim J. Kirkels ◽

Wolfgang Hoeltl ◽

Fernando Calais Da Silva ◽

...

Keyword(s):

High Risk ◽

Urothelial Carcinoma ◽

Phase 3 ◽

Term Efficacy ◽

Carcinoma Of The Bladder ◽

Intravesical Instillations

Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder

International braz j urol ◽

10.1590/s1677-55382010000400024 ◽

2010 ◽

Vol 36 (4) ◽

pp. 504-517

Author(s):

Andreas Bohle

Keyword(s):

High Risk ◽

Urothelial Carcinoma ◽

Phase 3 ◽

Term Efficacy ◽

Carcinoma Of The Bladder ◽

Intravesical Instillations